EPX-HTG for Structural Heart Procedures (EPX-HTG-2026)
EchoPixel Holographic Therapy Guidance (HTG) for Structural Heart Procedures
To investigate and evaluate the benefits of adding EchoPixel Holographic Therapy Guidance to the current standard of care in Structural Heart (SH) procedures.
Current structural heart (SH) procedures rely on standard image guidance (SIG) relies on 2D X-plane or multiplanar reformatted (MPR) views that can conceal critical anatomy elements at the time of implant or therapy delivery which are crucial to achieve an optimal long term durable outcome.
This limitation complicates an operator's task of optimally implanting a 3D device, delivered by tools that rotate and maneuver in 3D, within a dynamic 3D anatomy, the heart. Slight mismatches between the device and the target in the heart are indicative of a sub-optimal device position, a key risk-factor of peri-device leak (PDL) and other complications.
The primary objective of the study is to determine if including EchoPixel - HTG as an additive visualization procedural tool has a positive impact on optimal procedure outcomes for patients undergoing in Structural Heart (SH) procedures.
調査の概要
状態
詳細な説明
A prospective, single-center, clinical chart review.
In this trial, we will determine if the additional use of EchoPixel - HTG demonstrates a reduction in procedure time, decrease use of contrast and radiation, minimize the number of devices trialed during a procedure, determine ideal fluoroscopic viewing angles for device deployment, and optimize implant deployment and seal in in Structural Heart (SH) procedures.
The study team will compile the redacted pre- procedure CT, redacted procedural Trans-Esophageal Echo (TEE) or Intra-Cardiac Echo (ICE), procedural fluoroscopic imaging and the post device implant imaging created for each procedure case. Patient health information will be redacted and provided to physicians for review. Data will be collected on case report forms.
A prospective review will occur of outcomes regarding the Structural Heart (SH) procedure cases and data will be recorded on case report forms to compare to normal historical outcomes.
All available consecutive patients treated with the Watchman FLX device for Left Atrial Appendage Occlusion (LAAO) or MitraClip for Mitral Valve transcatheter edge to edge repair (M-TEER) will be reviewed. The primary endpoint will be to determine if EchoPixel - HTG assists in better guiding the implanter during the procedure.
All patients 18 and older scheduled for LAAO or M-TEER at the study site and whose procedure will use Philips CVx TEE or 3D ICE.
The Primary objective of the study is to determine if adding EchoPixel - HTG has a positive impact on optimal procedure success for patients undergoing an implantation of a Watchman FLX / MitraClip device compared to patients with current SIG. Procedural metrics and any procedural related complications will be recorded as secondary outcomes.
Patient demographics blinded procedural outcomes, pre-hospital discharge and complications will be monitored through and until the patient follow-up visit.
Study Execution.
Collection of data:
- All patients will be identified using a prospective review.
- The patients imaging will be de-identified and numbered with randomly picked research subject numbers identified only by site enrollment log (retained at the site only).
All deidentified data imaging will be downloaded on the two separate BOX (part 11 FDA compliant) drives.
- CT data in one drive.
- TEE data in one drive.
- ICE data in one drive.
- All patient's demographics will be obtained (age, ethnicity, vitals, ejection fraction, EKG, hemoglobin, creatinine, medical history, concomitant medications, CHADS2-Vasc, HAS-BLED, primary reason for implant).
Analysis of procedural data:
- Procedure time in minutes.
- Fluoroscopic time in minutes.
- Radiation dose in mGy.
- Contrast used during the LAAO procedure in ml.
- Number of devices trialed during the LAAO / TEER procedure.
- Number of attempted device deployments / recaptures.
- Clinical outcomes and procedural related complications.
- Composite of procedure-related complications through follow-up visit.
Informed Consent Process. This is a prospective trial, utilizing redacted personal health information (PHI). Therefore, consent will be obtained.
Privacy, Confidentiality and Data Handling. The investigator will retain all regulatory documents pertaining to this study in compliance with ICH/GCP guidelines. This includes essential study documents and source documentation that support the data collected on the study Subjects. Each subject's study data will be collected and will be securely stored in the coordinating site's office. Subjects will be identified using a subject identification number. Subject information will be anonymized for data analysis.
RISKS to PARTICIPANTS. As a prospective study, all patients will be managed according to the practice's standard-of-care. As a result, there are no additional risks to the patients having their medical charts reviewed for this study. Staff and employees at the study site have extensive HIPAA training and all records will be retained at the institution. Data collection will involve the recording of protected health information; however, this PHI data will remain at the study site and only de-identified data will be shared with Echopixel. The Watchman FLX procedure / MitraClip is an FDA approved procedure.
BENEFITS to PARTICIPANTS. As an FDA approved device and procedure, there is no direct benefit to the patient. However, information gained from the study will contribute to the body of knowledge regarding the treatment of patients needing the LAAO/MitraClip procedure. Additionally, future patients who may want to consider a LAAO/MitraClip procedure will benefit from the collective published literature base of studies, such as this proposed study.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Sergio Aguirre, MSc
- 電話番号:701 6503382559
- メール:sergio@echopixeltech.com
研究場所
-
-
California
-
Sacramento、California、アメリカ、95187
- University of California, Davis
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- All patients 18 and older scheduled for LAAO or M-TEER at the study site and whose procedure will use Philips CVx TEE or 3D ICE.
Exclusion Criteria:
- Patients whose procedures would require a GE or Siemens ultrasound system.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:EPX-HTG
Patients undergoing structural heart procedures (LAAO or M-TEER) including Holographic Therapy Guidance (HTG) as an additive visualization tool for procedure guidance.
|
Left Atrial Appendage Occlusion with HTG as an additive visualization tool for procedure guidance.
他の名前:
Mitral Valve Transcatheter Edge to Edge Repair with HTG as an additive visualization tool for procedure guidance.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Optimal Device Position.
時間枠:45 days post procedure.
|
For both LAAO and M-TEER procedures an optimal device position will be established in pre-procedure planning.
The optimal device position will be evaluated at the time of the procedure and in post-procedure imaging.
|
45 days post procedure.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Procedure Time.
時間枠:Perioperative/Periprocedural measurement of procedure length/duration.
|
Duration of procedure to implant LAAO or TEER device, in minutes.
|
Perioperative/Periprocedural measurement of procedure length/duration.
|
|
Fluoroscopic Time.
時間枠:Perioperative/Periprocedural measurement of length/duration of fluoroscopy use.
|
Duration/length of use of fluoroscopy to implant LAAO or TEER device, in minutes.
|
Perioperative/Periprocedural measurement of length/duration of fluoroscopy use.
|
|
Radiation Dose.
時間枠:Perioperative/Periprocedural measurement of total radiation dose for completing procedure/surgery.
|
Amount of radiation used to implant LAAO or TEER device in mGy.
|
Perioperative/Periprocedural measurement of total radiation dose for completing procedure/surgery.
|
|
Contrast Used.
時間枠:Perioperative/Periprocedural measurement of total radio-opaque contrast used for completing procedure/surgery.
|
Amount of radio-opaque contrast used to implant LAAO or TEER device, in ml.
|
Perioperative/Periprocedural measurement of total radio-opaque contrast used for completing procedure/surgery.
|
|
Number of devices trialed for procedure completion.
時間枠:Perioperative/Periprocedural count of the total number of devices (LAAO or TEER) utilized/required to complete the procedure/surgery.
|
The total number of devices (LAAO or TEER) utilized/required to complete the procedure.
|
Perioperative/Periprocedural count of the total number of devices (LAAO or TEER) utilized/required to complete the procedure/surgery.
|
|
Number of Device Deployments.
時間枠:Perioperative/Periprocedural count of the total number of times a device is positioned for final deployment in order to be released from the delivery catheter in order to complete the procedure/surgery/
|
The total number of times a device is positioned for final deployment in order to be released from the delivery catheter.
|
Perioperative/Periprocedural count of the total number of times a device is positioned for final deployment in order to be released from the delivery catheter in order to complete the procedure/surgery/
|
|
Procedure-related complications.
時間枠:Perioperative/Periprocedural and throughout 45-day follow-up visit.
|
Composite of any procedure-related complications for LAAO or M-TEER.
|
Perioperative/Periprocedural and throughout 45-day follow-up visit.
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Gagan D Singh, MD、UC Davis Health
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- EPX-HTG-2026
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。